Please login to the form below

Not currently logged in
Email:
Password:

Teva's MS drug disappoints in trial

Teva Pharmaceutical Industries has said its oral MS drug laquinimod has failed to reach its primary endpoint in a phase III trial but the company still plans regulatory submissions in the EU and US

Teva Pharmaceutical Industries has said its oral multiple sclerosis (MS) drug laquinimod has failed to reach its primary endpoint in a phase III trial.

Compared to placebo, the therapy, which is being investigated for use in the treatment of relapsing-remitting multiple sclerosis (RRMS), did not reduce annual relapse rates of the disease.

However, Teva said there were dissimilarities in the baseline magnetic resonance imaging (MRI) characteristics of the study group receiving placebo and the study group receiving laquinimod, affecting the trial's results.

When adjusted, laquinimod demonstrated a significant reduction in relapse rate for the disease, as well as a reduced risk of disability progression and brain volume loss.

Teva said additional analyses of the study data are ongoing, and the company still has plans to submit the drug for approval in both the EU and US.

Professor Yitzhak Peterburg, Teva's group vice-president, Global Branded Products, said: "Teva remains committed to the clinical development of laquinimod and is confident that the drug could provide a unique option for the treatment of multiple sclerosis."

2nd August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Finding the patient voice
How patients feel and speak about clinical trials...
Six Factors to Consider When Designing Advisory Boards
...
The good, the bad and the ugly
Tracking the pharmaceutical industry’s 2017 evolution and assessing how things may shape up in 2018 - it’s a trilogy of trends...

Infographics